Lin Xian, Yu Gui-Fang, Zuo Shi, Luo Rong-Cheng, Fang Wei-Yi
Integrated Hospital of Traditional Chinese Medicine, Southern Medical University Guangzhou, Guangdong, People's Republic of China.
Cancer Center, Southern Medical University Guangzhou, Guangdong, People's Republic of China.
Int J Clin Exp Pathol. 2018 May 1;11(5):2784-2791. eCollection 2018.
Hepatocellular carcinoma (HCC) is currently one of the most common causes of cancer-related death and one of the most commonly diagnosed cancers. MYH9 is thought to play a critical role in cancer progression. However, the expression and prognostic value of MYH9 in HCC are still unknown. In this study, the expression and biological significance of MYH9 were evaluated in HCC, at mRNA and protein levels. We showed that both mRNA and protein levels of MYH9 were significantly upregulated in HCC relative to the levels in adjacent non-tumor tissues based on the TCGA database and immunohistochemical analysis, respectively ( < 0.001). Additionally, we found that high MYH9 protein levels correlated with poor patient prognosis (median survival 19 months 49 months) (Log-Rank, = 0.0292). Meanwhile, our data suggested that MYH9 expression is an independent prognostic factor for HCC after surgical resection (HR = 0.675, 95% CI 0.452-1.008, = 0.054) and can potentially serve as a biomarker for the clinical diagnosis and prognosis of HCC.
肝细胞癌（HCC）是目前癌症相关死亡的最常见原因之一，也是最常被诊断出的癌症之一。MYH9被认为在癌症进展中起关键作用。然而，MYH9在HCC中的表达及预后价值仍不清楚。在本研究中，我们在mRNA和蛋白质水平评估了MYH9在HCC中的表达及生物学意义。基于TCGA数据库和免疫组化分析，我们发现相对于癌旁非肿瘤组织，HCC中MYH9的mRNA和蛋白质水平均显著上调（<0.001）。此外，我们发现MYH9蛋白水平高与患者预后差相关（中位生存期19个月对49个月）（对数秩检验，P = 0.0292）。同时，我们的数据表明MYH9表达是HCC手术切除后的独立预后因素（风险比=0.675，95%置信区间0.452 - 1.008，P = 0.054），并且有可能作为HCC临床诊断和预后的生物标志物。
